Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Sepsis is a heterogeneous syndrome comprising a highly diverse and dynamic mixture of hyperinflammatory and compensatory anti-inflammatory immune responses. This immune phenotypic diversity highlights the importance of proper patient selection for treatment with the immunomodulatory drugs that are entering clinical trials. To better understand the serial changes in immunity of critically ill patients and to evaluate the potential efficacy of blocking key inhibitory pathways in sepsis, we undertook a broad phenotypic and functional analysis of innate and acquired immunity in the same aliquot of blood from septic, critically ill nonseptic, and healthy donors. We also tested the ability of blocking the checkpoint inhibitors programmed death receptor-1 (PD-1) and its ligand (PD-L1) to restore the function of innate and acquired immune cells. Neutrophil and monocyte function (phagocytosis, CD163, cytokine expression) were progressively diminished as sepsis persisted. An increasing frequency in PD-L1+-suppressor phenotype neutrophils [low-density neutrophils (LDNs)] was also noted. PD-L1+LDNs and defective neutrophil function correlated with disease severity, consistent with the potential importance of suppressive neutrophil populations in sepsis. Reduced neutrophil and monocyte function correlated both with their own PD-L1 expression and with PD-1 expression on CD8+T cells and NK cells. Conversely, reduced CD8+T cell and NK cell functions (IFN-γ production, granzyme B, and CD107a expression) correlated with elevated PD-L1+LDNs. Importantly, addition of antibodies against PD-1 or PD-L1 restored function in neutrophil, monocyte, T cells, and NK cells, underlining the impact of the PD-1:PD-L1 axis in sepsis-immune suppression and the ability to treat multiple deficits with a single immunomodulatory agent.
Infectious Disease and Vaccines Department, MedImmune LLC, Gaithersburg, Maryland, USA pateraa@medimmune.com.
Andriani C
AC
Patera
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Anne M
AM
Drewry
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Katherine
K
Chang
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Evan R
ER
Beiter
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Dale
D
Osborne
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Richard S
RS
Hotchkiss
D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016638:Critical Illness; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology / Q000378:metabolism; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D011446:Prospective Studies; D018805:Sepsis / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D008070:Lipopolysaccharides; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D014409:Tumor Necrosis Factor-alpha
immunosuppression; monocytes; neutrophils; programmed cell death
J R Coll Physicians Lond. 2000 Sep-Oct;34(5):428-31
11077652
Am J Respir Crit Care Med. 2001 Feb;163(2):316-21
11179099
Crit Care Med. 2002 May;30(5):1056-61
12006803
Am J Pathol. 2002 Dec;161(6):2283-94
12466142
N Engl J Med. 2003 Jan 9;348(2):138-50
12519925
Shock. 2003 Feb;19(2):113-6
12578117
Crit Care Med. 2003 Apr;31(4):1250-6
12682500
Crit Care Med. 2004 Jul;32(7):1460-9
15241089
Crit Care. 2004 Dec;8(6):453-61
15566616
Crit Care Med. 2005 Aug;33(8):1814-22
16096460
Clin Exp Immunol. 2006 Feb;143(2):314-21
16412056
Acta Biochim Pol. 2006;53(2):257-68
16770444
Lancet. 2006 Jul 8;368(9530):157-69
16829300
Blood. 2009 Jan 22;113(4):887-92
18849484
J Immunol. 2008 Nov 1;181(9):6158-69
18941206
Nat Rev Immunol. 2008 Dec;8(12):958-69
19029990
J Clin Invest. 1991 Nov;88(5):1747-54
1939659
Infect Immun. 2010 Apr;78(4):1582-92
20100863
J Immunol. 2010 Apr 1;184(7):3768-79
20200277
Immunity. 2010 May 28;32(5):593-604
20510870
Mol Med. 2011 Mar-Apr;17(3-4):281-92
21085745
Int Immunopharmacol. 2011 Jul;11(7):802-7
21237299
Crit Care. 2011;15(1):R70
21349174
Nat Immunol. 2011 Jun;12(6):492-9
21739672
J Biomed Biotechnol. 2011;2011:451694
21960736
Ann Surg. 2012 Jan;255(1):158-64
21997806
J Clin Invest. 2012 Jan;122(1):327-36
22156198
JAMA. 2011 Dec 21;306(23):2594-605
22187279
J Clin Invest. 2012 Mar;122(3):787-95
22378047
Intensive Care Med. 2012 Jun;38(6):928-30
22552587
Shock. 2012 Jul;38(1):18-23
22575991
Shock. 2012 Aug;38(2):117-22
22683728
J Infect Dis. 2012 Aug 15;206(4):606-16
22693226
Crit Care. 2012 Jun 28;16(3):R112
22742734
Crit Care Med. 2013 Mar;41(3):820-32
23348516
Cell Mol Life Sci. 2013 Oct;70(20):3813-27
23423530
Lancet Infect Dis. 2013 Mar;13(3):260-8
23427891
N Engl J Med. 2013 Aug 29;369(9):840-51
23984731
Annu Rev Pathol. 2014;9:181-218
24050624
Virulence. 2014 Jan 1;5(1):45-56
24067565
Nat Rev Immunol. 2013 Dec;13(12):862-74
24232462
J Immunol. 2014 Feb 1;192(3):1091-9
24379123
Crit Care. 2014 Jan 04;18(1):R3
24387680
Trends Mol Med. 2014 Apr;20(4):224-33
24485901
PLoS Pathog. 2014 Mar 13;10(3):e1003993
24626392
Blood. 2014 Jul 31;124(5):710-9
24923297
J Leukoc Biol. 2014 Nov;96(5):685-93
24929004
Crit Care Med. 2014 Sep;42(9):2007-18
24942511
Crit Care. 2014 Aug 01;18(4):R163
25084831
J Clin Invest. 2014 Oct;124(10):4577-89
25180604
Anesthesiology. 2015 Apr;122(4):852-63
25437496
Cytometry B Clin Cytom. 2015 Mar;88(2):77-91
25504825
Mediators Inflamm. 2015;2015:159269
26078490
J Leukoc Biol. 2015 Dec;98(6):1081-90
26224052
Am J Respir Cell Mol Biol. 2016 Jan;54(1):13-24
26267148
J Immunol. 2015 Oct 15;195(8):3793-802
26371253
Shock. 2016 Jan;45(1):40-9
26674453
Intensive Care Med Exp. 2016 Dec;4(1):5
26879814
J Immunol. 1986 Jun 1;136(11):4220-5
3009619
Int Arch Allergy Appl Immunol. 1988;86(1):82-91
3286522
J Leukoc Biol. 1993 Feb;53(2):144-50
8445327
Shock. 1996;6 Suppl 1:S27-38
8828095
J Biol Chem. 1997 Jun 20;272(25):15613-9
9188449
Chest. 1997 Jul;112(1):235-43
9228382